Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2022 |
43068011304 |
Iloperidone 1 & 2 & 4 & 6 MG Tablet 8 EA |
07/16/2022 |
18.32 |
233.84 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2022 |
43068010102 |
Iloperidone 1 MG Tablet 60 EA |
07/16/2022 |
137.38 |
1753.63 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2022 |
43068011002 |
Iloperidone 10 MG Tablet 60 EA |
07/16/2022 |
270.71 |
3455.52 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2022 |
43068011202 |
Iloperidone 12 MG Tablet 60 EA |
07/16/2022 |
270.71 |
3455.52 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2022 |
43068010202 |
Iloperidone 2 MG Tablet 60 EA |
07/16/2022 |
137.38 |
1753.63 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2022 |
43068010402 |
Iloperidone 4 MG Tablet 60 EA |
07/16/2022 |
137.38 |
1753.63 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2022 |
43068010602 |
Iloperidone 6 MG Tablet 60 EA |
07/16/2022 |
169.04 |
2157.74 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2022 |
43068010802 |
Iloperidone 8 MG Tablet 60 EA |
07/16/2022 |
169.04 |
2157.74 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2022 |
43068022001 |
Tasimelteon 20 MG Capsule 30 EA |
07/16/2022 |
1865.22 |
23808.98 |
08/29/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2022 |
43068030406 |
Tasimelteon 4 MG/ML Suspension 158 ML |
07/16/2022 |
1964.70 |
25078.79 |
12/11/2040 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2022 |
43068030402 |
Tasimelteon 4 MG/ML Suspension 48 ML |
07/16/2022 |
596.87 |
7618.87 |
12/11/2040 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000416 |
Veloxis Pharmaceuticals, Inc. |
12/31/2022 |
68992307501 |
Envarsus XR .75mg 100 Tab |
12/23/2022 |
16.10 |
475.88 |
08/30/2028 |
Single Source Drug |
31741 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000416 |
Veloxis Pharmaceuticals, Inc. |
12/31/2022 |
68992307503 |
Envarsus XR .75mg 30 Tab |
12/23/2022 |
4.83 |
142.77 |
08/30/2028 |
Single Source Drug |
54789 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000416 |
Veloxis Pharmaceuticals, Inc. |
12/31/2022 |
68992301001 |
Envarsus XR 1mg 100 Tab |
12/23/2022 |
21.46 |
634.51 |
08/30/2028 |
Single Source Drug |
159730 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000416 |
Veloxis Pharmaceuticals, Inc. |
12/31/2022 |
68992301003 |
Envarsus XR 1mg 30 Tab |
12/23/2022 |
6.44 |
190.36 |
08/30/2028 |
Single Source Drug |
231804 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000416 |
Veloxis Pharmaceuticals, Inc. |
12/31/2022 |
68992304001 |
Envarsus XR 4mg 100 Tab |
12/23/2022 |
85.84 |
2538.00 |
08/30/2028 |
Single Source Drug |
47258 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000416 |
Veloxis Pharmaceuticals, Inc. |
12/31/2022 |
68992304003 |
Envarsus XR 4mg 30 Tab |
12/23/2022 |
25.76 |
761.40 |
08/30/2028 |
Single Source Drug |
82394 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000450 |
Vericel Corporation |
12/31/2022 |
69866103005 |
MACI; (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) 1 BAG in 1 BOX (69866-1030-5) > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-4) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-3) |
10/01/2022 |
3646.00 |
52252.00 |
11/25/2033 |
Single Source Drug |
None |
1 |
The Company is implementing this price increase to account for inflation and mitigate its rising cost of goods including the increased costs of materials from suppliers. |
None |
No improvement. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that while Vericel acquired MACI in 2014, the product was not launched until 06/27/2017, under the NDC # 69866-1030-01. The product was relabeled and given a new NDC # 69866-1030-05 with a market entry date 05/10/2021. |
Rx0000450 |
Vericel Corporation |
12/31/2022 |
69866103008 |
MACI; (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) 2 BAG in 1 BOX (69866-1030-8) > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-7) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-6) |
10/01/2022 |
7292.00 |
104504.00 |
11/25/2033 |
Single Source Drug |
None |
1 |
The Company is implementing this price increase to account for inflation and mitigate its rising cost of goods including the increased costs of materials from suppliers. |
None |
No improvement. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that while Vericel acquired MACI in 2014, the product was not launched until 06/27/2017, under the NDC # 69866-1030-02. The product was relabeled and given a new NDC # 69866-1030-08 with a market entry date 05/10/2021. |
Rx0000450 |
Vericel Corporation |
06/30/2022 |
69866103008 |
MACI; (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) 2 BAG in 1 BOX > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-7) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-6) |
06/17/2022 |
34664.00 |
97212.00 |
11/25/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that while Vericel acquired MACI in 2014, the product was not launched until 06/27/2017, under the NDC # 69866-1030-02. The product was relabeled and given a new NDC # 69866-1030-08 with a market entry date 05/10/2021. |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
09/30/2022 |
68025005230 |
Corvite 150 30 CT |
09/03/2022 |
11.96 |
161.41 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
09/30/2022 |
68025006030 |
Corvite Fe 30 CT |
09/03/2022 |
15.73 |
212.31 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
09/30/2022 |
68025006530 |
Divigel 0.1% 0.25 mg |
09/03/2022 |
6.57 |
168.60 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
09/30/2022 |
68025006630 |
Divigel 0.1% 0.5 mg |
09/03/2022 |
6.57 |
168.60 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
09/30/2022 |
68025008330 |
Divigel 0.1% 0.75 mg |
09/03/2022 |
6.57 |
168.60 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
09/30/2022 |
68025006730 |
Divigel 0.1% 1.0 mg |
09/03/2022 |
6.57 |
168.60 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
09/30/2022 |
68025008630 |
Divigel 0.1% 1.25 mg |
09/03/2022 |
6.57 |
168.60 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
09/30/2022 |
68025001010 |
OB Complete 100 CT |
09/03/2022 |
20.76 |
280.20 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
09/30/2022 |
68025004960 |
OB Complete DHA 60 CT |
09/03/2022 |
16.38 |
220.28 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
09/30/2022 |
68025004430 |
OB Complete One 30 CT |
09/03/2022 |
16.61 |
224.23 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
09/30/2022 |
68025005930 |
OB Complete Petite 30 CT |
09/03/2022 |
16.82 |
227.01 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
09/30/2022 |
68025004330 |
OB Complete Premier 30 CT |
09/03/2022 |
11.64 |
157.15 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
Rx0000414 |
Vifor Pharma Inc. |
06/30/2022 |
53436008404 |
Veltassa® (patiromer sorbitex calcium powder), for oral suspension 4 packets 8.4 grams |
04/01/2022 |
4.20 |
172.10 |
10/08/2033 |
Single Source Drug |
None |
1 |
Vifor bases pricing decisions, including price changes, on a range of market and
business considerations including market dynamics, the competitive environment,
inflationary costs associated with manufacturing, storage and supply, ongoing
pharmacovigilance, and other factors. Vifor sets prices to reflect the value of our
medicines to patients and society, enabling us to remain competitive. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=660 |
None |
Rx0000414 |
Vifor Pharma Inc. |
06/30/2022 |
53436016830 |
Veltassa® (patiromer sorbitex calcium powder), for oral suspension Veltassa® (patiromer sorbitex calcium powder), for oral suspension 30 packets 16.8 grams |
04/01/2022 |
23.56 |
965.92 |
10/08/2033 |
Single Source Drug |
None |
1 |
Vifor bases pricing decisions, including price changes, on a range of market and
business considerations including market dynamics, the competitive environment,
inflationary costs associated with manufacturing, storage and supply, ongoing
pharmacovigilance, and other factors. Vifor sets prices to reflect the value of our
medicines to patients and society, enabling us to remain competitive. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=662 |
None |
Rx0000414 |
Vifor Pharma Inc. |
06/30/2022 |
53436025230 |
Veltassa® (patiromer sorbitex calcium powder), for oral suspension Veltassa® (patiromer sorbitex calcium powder), for oral suspension 30 packets 25.2 grams |
04/01/2022 |
23.56 |
965.92 |
10/08/2033 |
Single Source Drug |
None |
1 |
Vifor bases pricing decisions, including price changes, on a range of market and
business considerations including market dynamics, the competitive environment,
inflationary costs associated with manufacturing, storage and supply, ongoing
pharmacovigilance, and other factors. Vifor sets prices to reflect the value of our
medicines to patients and society, enabling us to remain competitive. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=663 |
None |
Rx0000414 |
Vifor Pharma Inc. |
06/30/2022 |
53436008430 |
Veltassa® (patiromer sorbitex calcium powder), for oral suspension Veltassa® (patiromer sorbitex calcium powder), for oral suspension 30 packets 8.4 grams |
04/01/2022 |
23.56 |
965.92 |
10/08/2033 |
Single Source Drug |
None |
1 |
Vifor bases pricing decisions, including price changes, on a range of market and
business considerations including market dynamics, the competitive environment,
inflationary costs associated with manufacturing, storage and supply, ongoing
pharmacovigilance, and other factors. Vifor sets prices to reflect the value of our
medicines to patients and society, enabling us to remain competitive. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=661 |
None |